Simultaneous bilateral atypical femoral fracture in a patient receiving denosumab: case report and literature review

Osteoporosis International

Volumn 27, Issue 2, 2016, Pages 827-832

  Selga, J ^a   Nunez J H ^a   Minguell, J ^a   Lalanza, M ^a   Garrido, M ^a  

^a HOSPITAL UNIVERSITARI VALL D HEBRON   (Spain)

Author keywords

Atypical femoral fractures; Bisphosphonates; Denosumab; Osteoporosis

Indexed keywords

ALENDRONIC ACID; CALCIUM; DENOSUMAB; IBANDRONIC ACID; PARATHYROID HORMONE; PARATHYROID HORMONE[1-34]; RISEDRONIC ACID; VITAMIN D; BONE DENSITY CONSERVATION AGENT;

ADULT; ARTICLE; ATYPICAL FEMORAL FRACTURE; BONE RADIOGRAPHY; CASE REPORT; DRUG SAFETY; DRUG SUBSTITUTION; DRUG WITHDRAWAL; EMERGENCY WARD; FEMALE; FEMUR FRACTURE; FRACTURE HEALING; HUMAN; LEG FRACTURE; LEG PAIN; MIDDLE AGED; OSTEOPOROSIS; PATIENT MONITORING; POSTMENOPAUSE; PRIORITY JOURNAL; RADIUS FRACTURE; ULNA FRACTURE; WALKING DIFFICULTY; CHEMICALLY INDUCED; DIAGNOSTIC IMAGING; OSTEOPOROSIS, POSTMENOPAUSAL; RADIOGRAPHY; STRESS FRACTURE;

BONE DENSITY CONSERVATION AGENTS; DENOSUMAB; FEMALE; FEMORAL FRACTURES; FRACTURES, STRESS; HUMANS; MIDDLE AGED; OSTEOPOROSIS, POSTMENOPAUSAL; RADIOGRAPHY;

EID: 84957440346     PISSN: 0937941X     EISSN: 14332965     Source Type: Journal    
DOI: 10.1007/s00198-015-3355-z     Document Type: Article

References (31)

1. Johnell O, Kanis JA (2006) An estimate of the worldwide prevalence and disability associated with osteoporotic fractures. Osteoporos Int 17(12):1726–33. doi:10.1007/s00198-006-0172-4
2. Favus MJ (2010) Bisphosphonates for osteoporosis. N Engl J Med 363(21):2027–35. doi:10.1056/NEJMct1004903
3. Reginster JY (2011) Antifracture efficacy of currently available therapies for postmenopausal osteoporosis. Drugs 71(1):65–78. doi:10.2165/11587570-000000000-00000
4. Unnanuntana A, Saleh A, Mensah KA, Kleimeyer JP, Lane JM (2013) Atypical femoral fractures: what do we know about them?: AAOS Exhibit Selection. J Bone Joint Surg Am 95(2):e8 1–13. doi:10.2106/JBJS.L.00568
5. Cummings SR, San Martin J, McClung MR, Siris ES, Eastell R, Reid IR, Delmas P, Zoog HB, Austin M, Wang A, Kutilek S, Adami S, Zancetta J, Libanati C, Siddhanti S, Christiansen C (2009) Denosumab for prevention of fractures in postmenopausal women with osteoporosis. N Engl J Med 361(8):756–65. doi:10.1056/NEJMoa0809493
6. Aspenberg P (2014) Denosumab and atypical femoral fractures. Acta Orthop 85(1):1–2. doi:10.3109/17453674.2013.859423
7. Neviaser AS, Lane JM, Lenart BA, Edobor-Osula F, Lorich DG (2008) Low energy femoral shaft fractures associated with alendronate use. J Orthop Trauma 22(5):346–50. doi:10.1097/BOT.0b013e318172841c
8. Silverman S, Christiansen C (2012) Individualizing osteoporosis therapy. Osteoporos Int 23(3):797–809. doi:10.1007/s00198-011-1775-y
9. Min YK (2015) Update on denosumab treatment in postmenopausal women with osteoporosis. Endocrinol Metab 30(1):19–26. doi:10.3803/EnM.2015.30.1.19
10. Balach T, Baldwin PC, Intravia J (2015) Atypical femur fractures associated with diphosphonate use. J Am Acad Orthop Surg 23(9):550–7. doi:10.5435/JAAOS-D-14-00024
11. Dell RM, Adams AL et al (2012) Incidence of atypical nontraumatic diaphyseal fractures of the femur. J Bone Miner Res 27(12):2544–50. doi:10.1002/jbmr.1719
12. Seraphim A, Al-Hadithy N, Mordecai SC, Al-Nammari S (2012) Do bisphosphonates cause femoral insufficiency fractures? J Orthop Traumatol 13(4):171–7. doi:10.1007/s10195-012-0207-x
13. Ettinger B, Burr DB, Ritchie RO (2013) Proposed pathogenesis for atypical femoral fractures: lessons from materials research. Bone 55(2):495–500. doi:10.1016/j.bone.2013.02.004
14. S. Papapoulos, K. Lippuner, et al. The effect of 8 or 5 years of denosumab treatment in postmenopausal women with osteoporosis: results from the FREEDOM Extension study. Osteoporos Int. 2015 Jul 23. [Epub ahead of print]. doi: 10.1007/s00198-015-3234-7.
15. Paparodis R, Buehring B, Pelley EM, Binkley N (2013) A case of an unusual subtrochanteric fracture in a patient receiving denosumab. Endocr Pract 19(3):e64–8. doi:10.4158/EP12367.CR
16. Thompson RN, Armstrong CL, Heyburn G (2014) Bilateral atypical femoral fractures in a patient prescribed denosumab–a case report. Bone 61:44–7. doi:10.1016/j.bone.2013.12.027
17. Villiers J, Clark DW, Jeswani T, Webster S, Hepburn AL (2013) An atraumatic femoral fracture in a patient with rheumatoid arthritis and osteoporosis treated with denosumab. Case Rep Rheumatol 2013:249872. doi:10.1155/2013/249872
18. Drampalos E, Skarpas G, Barbounakis N, Michos I (2014) Atypical femoral fractures bilaterally in a patient receiving denosumab. Acta Orthop 85(1):3–5. doi:10.3109/17453674.2013.854668
19. Schilcher J, Aspenberg P (2014) Atypical fracture of the femur in a patient using denosumab—a case report. Acta Orthop 85(1):6–7. doi:10.3109/17453674.2014.885355
20. Khow KSF, Yong TY (2015) Atypical femoral fracture in a patient treated with denosumab. J Bone Miner Metab 33(3):355–8. doi:10.1007/s00774-014-0606-6
21. Shane E, Burr D, Abrahamsen B, Adler RA, Brown TD et al (2014) Atypical subtrochanteric and diaphyseal femoral fractures: second report of a task force of the American Society for Bone and Mineral Research. J Bone Miner Res 29(1):1–23. doi:10.1002/jbmr.1998
22. Khan SA, Kanis JA et al (1997) Elimination and biochemical responses to intravenous alendronate in postmenopausal osteoporosis. J Bone Miner Res 12(10):1700–7. doi:10.1359/jbmr.1997.12.10.1700
23. Craig M, Capeci MD, Nirmal C, Tejwani MD (2009) Bilateral low-energy simultaneous or sequential femoral fractures in patients on long-term alendronate therapy. J Bone Joint Surg Am 91(11):2556–61. doi:10.2106/JBJS.H.01774
24. Patel VC, Lazzarini AM (2010) Bilateral simultaneous femoral diaphyseal fractures in a patient with long-term ibandronate use. Orthopedics 33(10):775. doi:10.3928/01477447-20100826-31
25. Puah KL, Tan MH (2011) Bisphosphonate-associated atypical fracture of the femur: Spontaneous healing with drug holiday and re-appearance after resumed drug therapy with bilateral simultaneous displaced fractures--a case report. Acta Orthop 82(3):380–2. doi:10.3109/17453674.2011.581267
26. Ovaska MT, Mäkinen TJ, Madanat R (2011) Simultaneous bilateral subtrochanteric fractures following risedronate therapy. J Orthop Sci 16(4):467–70. doi:10.1007/s00776-011-0058-y
27. Zafeiris CP, Stathopoulos IP, Kourkoumelis G, Gkikas E, Lyritis GP (2012) Simultaneous bilateral atypical femoral fractures after alendronate therapy. J Musculoskelet Neuronal Interact 12(4):262–4
28. Schilcher J, Michaëlsson K, Aspenberg P (2011) Bisphosphonate use and atypical fractures of the femoral shaft. N Engl J Med 364(18):1728–37. doi:10.1056/NEJMoa1010650
29. Banffy MB, Vrahas MS, Ready JE, Abraham JA (2011) Nonoperative versus prophylactic treatment of bisphosphonate-associated femoral stress fractures. Clin Orthop Relat Res 469(7):2028–34. doi:10.1007/s11999-011-1828-8
30. Weil YA, Rivkin G, Safran O, Liebergall M, Foldes AJ (2011) The outcome of surgically treated femur fractures associated with long-term bisphosphonate use. J Trauma 71(1):186–90. doi:10.1097/TA.0b013e31821957e3
31. Teo BJ, Koh JS, Goh SK, Png MA, Chua DT, Howe TS (2014) Post-operative outcomes of atypical femoral subtrochanteric fracture in patients on bisphosphonate therapy. Bone Joint J 96-B(5):658–64. doi:10.1302/0301-620X.96B5.32887